ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting
Oegstgeest, The Netherlands, 27 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be presenting data evaluating the response to its T cell inducing SLP therapy against SARS-CoV-2 in collaboration with the Leiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR) at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), being held in Mainz, Germany on 3-5 May, 2023.
